Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-18 June 2026

The Committee for Veterinary Medicinal Products (CVMP) held a meeting from 16 to 18 June 2026. During the meeting, the committee adopted a negative opinion on the marketing authorisation for the product Scovella (velagliflozin). This product was classified in a specific category of veterinary medicines. A negative opinion means that the committee did not recommend approval of this medicine for the market. The meeting addressed the assessment of safety and efficacy of the submitted veterinary medicine. The CVMP committee is responsible for issuing expert opinions on veterinary medicines in the European Union.